dactinomycin has been researched along with Infusion Site Adverse Event in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves-Ferreira, M; Bin, S; Bolze, PA; Devouassoux-Shisheboran, M; Freyer, G; Gladieff, L; Golfier, F; Grazziotin-Soares, D; Hajri, T; Joly, F; Langlois-Jacques, C; Lotz, JP; Massardier, J; Maucort-Boulch, D; Mercier, C; Rousset, P; Roux, A; Villeneuve, L; You, B | 1 |
1 trial(s) available for dactinomycin and Infusion Site Adverse Event
| Article | Year |
|---|---|
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
Topics: Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Chorionic Gonadotropin; Dactinomycin; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Injection Site Reaction; Methotrexate; Middle Aged; Nausea; Pregnancy; Retreatment; Vomiting; Young Adult | 2020 |